Clinical potential of the ERG oncoprotein in prostate cancer

@article{Rosen2012ClinicalPO,
  title={Clinical potential of the ERG oncoprotein in prostate cancer},
  author={Philip C. Rosen and Isabell A. Sesterhenn and Stephen A. Brassell and David G. Mcleod and Sundaresha S. Nidhi Srivastava and Albert Dobi},
  journal={Nature Reviews Urology},
  year={2012},
  volume={9},
  pages={131-137}
}
Oncogenic activation of ERG resulting from gene fusion is present in over half of all patients with prostate cancer in Western countries. Although the underlying genetic mechanisms have been extensively studied, evaluation of the ERG oncoprotein—the translational product of ERG gene fusions—has just begun. The robust correlation between ERG oncoprotein detection and gene fusion status enables rapid characterization of this protein in large patient cohorts. Recent studies have focused on… CONTINUE READING
BETA

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 29 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 87 REFERENCES

Similar Papers

Loading similar papers…